Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew D Hellmann

Showing results (151-160 of 172) with videos related to

Pageof 18
Sort By:
Cancer Discovery|March 25, 2017
Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging TherapiesEmmet J Jordan, Hyunjae R Kim, Maria E Arcila, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 13, 2020
Circulating Tumor DNA Analysis to Assess Risk of Progression after Long-term Response to PD-(L)1 Blockade in NSCLCMatthew D Hellmann, Barzin Y Nabet, Hira Rizvi, et al.
Journal of the National Cancer Institute|November 30, 2018
A Prospective Study of Circulating Tumor DNA to Guide Matched Targeted Therapy in Lung CancersJoshua K Sabari, Michael Offin, Dennis Stephens, et al.
Cancer Cell|June 11, 2021
Tim-4<sup>+</sup> cavity-resident macrophages impair anti-tumor CD8<sup>+</sup> T cell immunityAndrew Chow, Sara Schad, Michael D Green, et al.
Cell|October 10, 2020
Key Parameters of Tumor Epitope Immunogenicity Revealed Through a Consortium Approach Improve Neoantigen PredictionDaniel K Wells, Marit M van Buuren, Kristen K Dang, et al.
JAMA Oncology|June 16, 2022
Association of High Tumor Mutation Burden in Non-Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression LevelsBiagio Ricciuti, Xinan Wang, Joao V Alessi, et al.
Science (New York, N.Y.)|November 4, 2017
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumorsBertrand Routy, Emmanuelle Le Chatelier, Lisa Derosa, et al.
Nature Genetics|April 6, 2023
Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancerArvind Ravi, Matthew D Hellmann, Monica B Arniella, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 5, 2020
New Approaches to SCLC Therapy: From the Laboratory to the ClinicJohn T Poirier, Julie George, Taofeek K Owonikoko, et al.
JCO Precision Oncology|September 12, 2017
OncoKB: A Precision Oncology Knowledge BaseDebyani Chakravarty, Jianjiong Gao, Sarah M Phillips, et al.
Pageof 18

Showing results (151-160 of 172) with videos related to

Sort By:
Pageof 18
Cancer Discovery|March 25, 2017
Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging TherapiesEmmet J Jordan, Hyunjae R Kim, Maria E Arcila, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 13, 2020
Circulating Tumor DNA Analysis to Assess Risk of Progression after Long-term Response to PD-(L)1 Blockade in NSCLCMatthew D Hellmann, Barzin Y Nabet, Hira Rizvi, et al.
Journal of the National Cancer Institute|November 30, 2018
A Prospective Study of Circulating Tumor DNA to Guide Matched Targeted Therapy in Lung CancersJoshua K Sabari, Michael Offin, Dennis Stephens, et al.
Cancer Cell|June 11, 2021
Tim-4<sup>+</sup> cavity-resident macrophages impair anti-tumor CD8<sup>+</sup> T cell immunityAndrew Chow, Sara Schad, Michael D Green, et al.
Cell|October 10, 2020
Key Parameters of Tumor Epitope Immunogenicity Revealed Through a Consortium Approach Improve Neoantigen PredictionDaniel K Wells, Marit M van Buuren, Kristen K Dang, et al.
JAMA Oncology|June 16, 2022
Association of High Tumor Mutation Burden in Non-Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression LevelsBiagio Ricciuti, Xinan Wang, Joao V Alessi, et al.
Science (New York, N.Y.)|November 4, 2017
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumorsBertrand Routy, Emmanuelle Le Chatelier, Lisa Derosa, et al.
Nature Genetics|April 6, 2023
Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancerArvind Ravi, Matthew D Hellmann, Monica B Arniella, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 5, 2020
New Approaches to SCLC Therapy: From the Laboratory to the ClinicJohn T Poirier, Julie George, Taofeek K Owonikoko, et al.
JCO Precision Oncology|September 12, 2017
OncoKB: A Precision Oncology Knowledge BaseDebyani Chakravarty, Jianjiong Gao, Sarah M Phillips, et al.
Pageof 18